Quantcast
Browsing all 3524 articles
Browse latest View live

Atea ends development of inhibitor candidate as Covid-19 treatment following...

Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase inhibitor, which it was investigating as a Covid-19 treatment. The Phase 3...

View Article


Image may be NSFW.
Clik here to view.

Post-Hoc: Big promises built Moderna. They might also be its undoing

(This is a preview of Post-Hoc, our latest newsletter with analysis and dispatches from our journalists. To sign up for future editions, click here.) One of my distinct memories of the early pandemic...

View Article


After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC...

The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC. Zymergen’s rise began in April 2021 with an outsized $500 million IPO, capping a remarkable run...

View Article

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Arbor Biotechnologies is trimming its early-stage discovery work, leading to layoffs in the group. The move was confirmed by an Arbor spokesperson, with CEO Devyn Smith saying in a statement to...

View Article

Adcomm says Intercept's rare liver disease drug should not get full approval

An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva by a 13-1 vote, concluding that confirmatory evidence didn’t...

View Article


SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

The SEC’s investigation into the $8 billion deal between Grail and Illumina is examining sales forecasts made by Grail’s management in the run-up to the 2021 transaction, according to sources familiar...

View Article

Image may be NSFW.
Clik here to view.

#ESMO24: GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2...

BARCELONA — GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, bolstering expectations for an ongoing Phase 3 trial that is testing...

View Article

Image may be NSFW.
Clik here to view.

#ESMO24: Nuvation Bio outlines pooled data for former AnHeart drug in...

Nuvation Bio outlined pooled data from its two Phase 2 studies at the annual European Society for Medical Oncology confab in Barcelona this weekend as it prepares to approach the FDA soon. The company...

View Article


House passes Biosecure Act; Moderna outlines more cost cuts; What's happening...

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...

View Article


Image may be NSFW.
Clik here to view.

#ESMO24: Bristol Myers touts LAG-3 strategy in lung cancer as it preps for...

BARCELONA — Bristol Myers Squibb’s LAG-3 approach has shown potential in certain lung cancer patients in a Phase 2 study, drawing some reassurance in its planned late-stage trial against Merck’s...

View Article

Image may be NSFW.
Clik here to view.

#ESMO24: Pfizer tees up Phase 3 in 2025 in weight management, but in an...

BARCELONA — At a major cancer conference, Pfizer made an unexpected announcement: It has late-stage plans in weight management. But it’s not targeting weight loss like one would first think amid the...

View Article

#ESMO24: Incyte gears up to face FDA once again with more Zynyz data in rare...

BARCELONA — Incyte said it has positive late-phase results for its PD-1 drug Zynyz in certain patients with squamous cell carcinoma, three years after the FDA asked for more data. The Phase 3...

View Article

Physical therapy startup Sword Health shifts to a novel way of getting paid

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)  An AI-powered digital physical therapy startup is the latest health tech company to switch to a...

View Article


Image may be NSFW.
Clik here to view.

#ESMO24: Merck's Eliav Barr on subcutaneous Keytruda, Summit's data, 'fetch...

BARCELONA — In the span of 30 minutes, 29-year Merck veteran Eliav Barr can analogize drug development dealmaking to Reese’s candy, call himself an “old fart” when asked about career plans, get real...

View Article

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

BARCELONA — Immatics presented more clinical data on its bispecific T cell engager at Europe’s largest cancer conference. But the German and US biotech is losing its partner on the Phase 1 drug, which...

View Article


Image may be NSFW.
Clik here to view.

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's...

Kyverna Therapeutics has reshaped its C-suite just seven months after securing one of the splashiest biotech IPOs in recent years as it rode the waves of cell therapy’s expansion into the autoimmune...

View Article

Image may be NSFW.
Clik here to view.

Ochre Bio CEO Jack O’Meara steps down, outlines plans for next startup

Jack O’Meara announced on LinkedIn Monday that he is stepping down from the CEO post at Ochre Bio, the liver disease startup he co-founded. In an interview with Endpoints News, he teased plans for a...

View Article


Nuvalent's $350M offering; FDA lifts partial hold on Zentalis drug

Plus, news about Ascendis Pharma, Korro Bio, Novo Nordisk and Medexus: Nuvalent offers $350M in shares: The oncology biotech is looking to capitalize on a swell of investor interest, with its share...

View Article

Image may be NSFW.
Clik here to view.

#ESMO24: BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take...

BARCELONA — Last week, Summit and Akeso set the industry abuzz after their bispecific antibody beat Merck’s Keytruda in a Phase 3 lung cancer trial. Now, BioNTech is touting mid-stage data for its own...

View Article

Image may be NSFW.
Clik here to view.

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets 

Roche has already budgeted for future commercial manufacturing builds and established a network of contract manufacturers as it preps for the launch of its GLP-1/GIP drugs. The company discussed its...

View Article
Browsing all 3524 articles
Browse latest View live